Proethic Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 15 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.77 M
- Satisfied Charges ₹ 1.20 M
- Revenue Growth -54.10%
- Profit Growth -241.83%
- Ebitda 16012.81%
- Net Worth -10.76%
- Total Assets -16.18%
About Proethic Pharmaceuticals
Proethic Pharmaceuticals Private Limited (PPPL) is a Private Limited Indian Non-Government Company incorporated in India on 12 October 2009 and has a history of 15 years and three months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹0.77 M. The company has closed loans amounting to ₹1.20 M, as per Ministry of Corporate Affairs (MCA) records.
Vikas Malik and Kamlesh serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232DL2009PTC195127
-
Company No.
195127
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
12 Oct 2009
-
Date of AGM
27 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Proethic Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikas Malik
|
Director | 12-Oct-2009 | Current |
|
Kamlesh
|
Director | 09-Mar-2018 | Current |
Financial Performance of Proethic Pharmaceuticals.
Proethic Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 54.1% decrease. The company also saw a substantial fall in profitability, with a 241.83% decrease in profit. The company's net worth observed a substantial decline by a decrease of 10.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Proethic Pharmaceuticals?
In 2020, Proethic Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.77 M
₹1.20 M
Charges Breakdown by Lending Institutions
- Others : 0.08 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Jul 2018 | Others | ₹0.77 M | Open |
| 18 Dec 2010 | Canara Bank | ₹1.20 M | Satisfied |
How Many Employees Work at Proethic Pharmaceuticals?
Unlock and access historical data on people associated with Proethic Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Proethic Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Proethic Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
